Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Neuren Pharmaceuticals Limited (NEU.AX)
AUD17.54
+0.85 (+5.09%)
AU ASX Healthcare Biotechnology
Address
117 Camberwell Road 3123
Hawthorn East, VIC, AU
Hawthorn East, VIC, AU
CEO
Jonathan Charles Pilcher
Website
neurenpharma.com
IPO
2005-02-01
ISIN NZNEUE0001S8
Also trades on
Australian Securities Exchange · NEU.AX (AUD)
Other OTC · NURPF (USD)
Description
Neuren Pharmaceuticals Limited, a biopharmaceutical company, develops drugs for the treatment of neurological disorders. It develops and commercializes DAYBUE (trofinetide) for the treatment of Rett syndrome in adults and pediatric patients 2 years of age and older, as well as in Phase 2 clinical trial to treat Fragile X syndrome. The company also develops NNZ-2591, which has completed Phase 2 clinical trial for the treatment of Phelan-McDermid; and in Phase 2 clinical trial for the treatment of Angelman and Pitt Hopkins. In addition, it develops NNZ-2591, which is in Preclinical trial stage for the treatment of Prader-Willi syndrome. The company was incorporated in 2001 and is based in Hawthorn East, Australia.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
AUD17.54
+0.85 (+5.09%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
411.9K
Beta
1.59
Float Shares
107.85M
Free Float %
85.3%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +5.36% | +5.36% | +16.69% | +11.42% | -25.97% | -21.87% | +7.15% | +5.06% | +1,018.46% | +985.07% | +154.64% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
17.54
DCF (Unlevered)
0.78
-95.6%
DCF (Levered)
3.65
-79.2%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
100% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 5 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
255.29
Safe zone
Piotroski F-Score
6 / 9
Average
MOAT Score
5 / 10
Developing
Composite Rating
B-
Overall Score
3 / 5
Medium
DCF Score
3 / 5
Medium
ROE Score
4 / 5
High
ROA Score
5 / 5
High
D/E Score
1 / 5
Low
P/E Score
1 / 5
Low
P/Book Score
1 / 5
Low
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%-69.7% Q4'25: -78.5% (vs Q4'23)
-
EPS growth Biotechnology: +29.7%-78.9% Q4'25: -85.5% (vs Q4'23)
-
FCF margin FCF growth · Biotechnology: +16.2%+169.5% Q4'25: -8.0% (vs Q4'23)
-
EBIT margin Biotechnology: +0.0%+34.1% ★ Q4'25: +30.6% (vs Q4'23)
-
ROIC Biotechnology: -16.1%+40.7% ★ Q4'25: +84.3% (vs Q4'23)
-
Share dilution Biotechnology: -3.4%0.0% ★ Q4'25: +1.1% (vs Q4'23)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×0.00× ★ Q4'25: 0.00× (vs Q4'23)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2012 actual |
Dec 2013 actual |
Dec 2014 actual |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 4 Rev. Ana. 4 EPS Ana. |
Dec 2027 4 Rev. Ana. 4 EPS Ana. |
Dec 2028 4 Rev. Ana. 4 EPS Ana. |
Dec 2029 3 Rev. Ana. 2 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
—
est: 3.22M (-100.0%)
|
4.79M
est: 3.81M (+25.8%)
|
2.93M
est: 2.94M (-0.4%)
|
1.67M
est: 2.30M (-27.3%)
|
3.15M
est: 3.10M (+1.6%)
|
631.0K
est: 800.0K (-21.1%)
|
13.99M
est: 13.90M (+0.6%)
|
495.0K
est: 400.0K (+23.8%)
|
717.0K
est: 14.50M (-95.1%)
|
3.20M
est: 1.90M (+68.3%)
|
14.55M
est: 15.42M (-5.6%)
|
231.93M
est: 193.34M (+20.0%)
|
213.24M
est: 213.24M (+0.0%)
|
64.63M
est: 67.61M (-4.4%)
|
76.02M
71.73M – 86.53M
+12.4% YoY
|
162.38M
85.75M – 210.95M
+113.6% YoY
|
246.07M
164.19M – 306.43M
+51.5% YoY
|
1.20B
803.02M – 1.50B
+389.1% YoY
|
| EBITDA |
-4.76M
est: -234.2K (-1,932.9%)
|
-9.02M
est: -271.6K (-3,221.8%)
|
-8.22M
est: -209.8K (-3,816.2%)
|
-14.06M
est: -5.89M (-138.5%)
|
-13.78M
est: -17.67M (+22.0%)
|
2.74M
est: -2.94M (+193.1%)
|
5.37M
est: -1.01M (+631.3%)
|
-11.31M
est: -1.74M (-548.4%)
|
-9.90M
est: -24.42M (+59.4%)
|
-10.98M
est: -140.4K (-7,724.7%)
|
-670.0K
est: -1.46B (+100.0%)
|
199.26M
est: 37.80M (+427.1%)
|
175.57M
est: -1.35T (+100.0%)
|
22.05M
est: 13.22M (+66.8%)
|
14.86M
14.02M – 16.92M
+12.4% YoY
|
31.75M
16.77M – 41.24M
+113.6% YoY
|
48.11M
32.10M – 59.91M
+51.5% YoY
|
235.30M
157.00M – 293.02M
+389.1% YoY
|
| EBIT |
-5.12M
est: -234.8K (-2,079.9%)
|
-10.47M
est: -5.89M (-77.8%)
|
-8.32M
est: -7.05M (-18.0%)
|
-15.58M
est: -7.30M (-113.4%)
|
-13.86M
est: -20.65M (+32.9%)
|
-6.07M
est: -2.85M (-113.1%)
|
5.82M
est: -1.01M (+674.0%)
|
-11.31M
est: -1.69M (-568.9%)
|
-9.91M
est: -23.84M (+58.4%)
|
-10.99M
est: -140.7K (-7,711.8%)
|
-680.0K
est: -1.42B (+100.0%)
|
199.21M
est: 37.75M (+427.7%)
|
175.55M
est: -1.32T (+100.0%)
|
22.02M
est: 13.20M (+66.8%)
|
14.84M
14.01M – 16.90M
+12.4% YoY
|
31.71M
16.74M – 41.19M
+113.6% YoY
|
48.05M
32.06M – 59.84M
+51.5% YoY
|
235.01M
156.81M – 292.66M
+389.1% YoY
|
| Net Income |
-5.09M
est: -10.55M (+51.7%)
|
-11.30M
est: -10.91M (-3.5%)
|
-8.30M
est: -8.06M (-2.9%)
|
-13.40M
est: -6.59M (-103.2%)
|
-12.01M
est: -18.15M (+33.8%)
|
3.29M
est: -2.89M (+213.6%)
|
3.07M
est: -4.58M (+167.1%)
|
-10.82M
est: -1.72M (-529.8%)
|
-9.19M
est: -24.13M (+61.9%)
|
-7.79M
est: -14.02M (+44.4%)
|
184.0K
est: 55.04M (-99.7%)
|
157.08M
est: 117.29M (+33.9%)
|
142.04M
est: 149.06M (-4.7%)
|
30.44M
est: 16.11M (+88.9%)
|
14.25M
-1.64M – 31.72M
-11.6% YoY
|
58.15M
7.09M – 155.22M
+308.1% YoY
|
174.57M
52.62M – 284.83M
+200.2% YoY
|
694.58M
394.11M – 916.06M
+297.9% YoY
|
| SGA |
2.59M
est: 2.15M (+20.7%)
|
2.97M
est: 2.49M (+19.4%)
|
2.64M
est: 1.92M (+37.2%)
|
3.12M
est: 2.02M (+54.6%)
|
1.76M
est: 2.06M (-14.7%)
|
1.49M
est: 443.7K (+235.8%)
|
2.07M
est: 9.26M (-77.6%)
|
1.71M
est: 263.3K (+549.0%)
|
1.76M
est: 3.82M (-54.0%)
|
1.91M
est: 1.27M (+50.6%)
|
3.43M
est: 10.27M (-66.6%)
|
5.95M
est: 37.71M (-84.2%)
|
4.70M
est: 41.59M (-88.7%)
|
6.20M
est: 13.19M (-53.0%)
|
14.83M
13.99M – 16.88M
+12.4% YoY
|
31.67M
16.72M – 41.14M
+113.6% YoY
|
47.99M
32.02M – 59.77M
+51.5% YoY
|
234.73M
156.62M – 292.31M
+389.1% YoY
|
| EPS |
-0.09
est: -0.08 (-7.6%)
|
-0.18
est: -0.08 (-115.2%)
|
-0.11
est: -0.10 (-10.0%)
|
-0.16
est: -0.14 (-14.3%)
|
-2.84
est: -0.12 (-2,266.7%)
|
0.04
est: -0.07 (+148.6%)
|
0.03
est: -0.04 (+188.6%)
|
-0.11
est: -0.14 (+19.7%)
|
-0.09
est: -0.10 (+16.6%)
|
-0.07
est: -0.11 (+37.0%)
|
0.00
est: -0.02 (+108.6%)
|
1.24
est: 0.92 (+35.0%)
|
1.11
est: 1.09 (+2.2%)
|
0.24
est: 0.12 (+98.7%)
|
0.12
-0.01 – 0.24
-2.6% YoY
|
0.52
0.05 – 1.19
+337.9% YoY
|
1.17
0.40 – 2.18
+128.1% YoY
|
5.31
3.01 – 7.01
+352.2% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | B- | 3/5 | 3/5 | 4/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-28 | B- | 3/5 | 3/5 | 4/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-27 | B- | 3/5 | 3/5 | 4/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-26 | B- | 3/5 | 3/5 | 4/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-25 | B- | 3/5 | 3/5 | 4/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-22 | B- | 3/5 | 3/5 | 4/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-21 | B- | 3/5 | 3/5 | 4/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-20 | B- | 3/5 | 3/5 | 4/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-19 | B- | 3/5 | 3/5 | 4/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-18 | B- | 3/5 | 3/5 | 4/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-15 | B- | 3/5 | 3/5 | 4/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-14 | B- | 3/5 | 3/5 | 4/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-13 | B- | 3/5 | 3/5 | 4/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-12 | B- | 3/5 | 3/5 | 4/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-11 | B- | 3/5 | 3/5 | 4/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-08 | B- | 2/5 | 3/5 | 3/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-07 | B- | 2/5 | 3/5 | 3/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-06 | B- | 2/5 | 3/5 | 3/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-05 | B- | 2/5 | 3/5 | 3/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-04 | B- | 2/5 | 3/5 | 3/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-01 | B- | 2/5 | 3/5 | 3/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-30 | B- | 2/5 | 3/5 | 3/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-29 | B- | 2/5 | 3/5 | 3/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-28 | B- | 2/5 | 3/5 | 3/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-27 | B- | 2/5 | 3/5 | 3/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-24 | B- | 2/5 | 3/5 | 3/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-23 | B- | 2/5 | 3/5 | 3/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-22 | B- | 2/5 | 3/5 | 3/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-21 | B- | 2/5 | 3/5 | 3/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-20 | B- | 2/5 | 3/5 | 3/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-17 | B- | 2/5 | 3/5 | 3/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-16 | B- | 2/5 | 3/5 | 3/5 | 5/5 | 1/5 | 1/5 | 1/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
114.10M
OE per share TTM
0.89
Owner's Yield
6.20%
Maintenance CapEx ratio
0.49%
Maint CapEx / Avg PPE
0.0%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
Held by 84 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | BetaShares - Australian Small Companies Select ETF SMLL.AX | 1.86% | 4.34M | 0.39% |
| 2 | iShares S&P/ASX Small Ordinaries ETF ISO.AX | 0.73% | 636.9K | 0.55% |
| 3 | BetaShares - Australian Sustainability Leaders ETF FAIR.AX | 0.36% | 2.69M | 0.49% |
| 4 | Vanguard MSCI Australian Small Companies Index ETF VSO.AX | 0.31% | 2.44M | 0.30% |
| 5 | BetaShares - Australian Ex-20 Portfolio Diversifier ETF EX20.AX | 0.19% | 865.8K | 0.25% |
| 6 | BetaShares - Geared Australian Equities Complex ETF GEAR.AX | 0.17% | 731.8K | 0.78% |
| 7 | iShares Healthcare Innovation UCITS ETF HEAL.L | 0.16% | 1.83M | 0.40% |
| 8 | iShares Ageing Population UCITS ETF AGED.L | 0.13% | 1.12M | 0.40% |
| 9 | State Street SPDR S&P International Small Cap ETF GWX | 0.11% | 937.6K | 0.40% |
| 10 | iShares International Small-Cap Equity Factor ETF ISCF | 0.09% | 566.8K | 0.24% |
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
EBIT / Employee
2.45M
Shares Outstanding
126.50M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Jonathan Charles Pilcher | Chief Executive Officer, MD & Executive Director | 837.5K | male |
| Daryl Dekarske | Chief Regulatory Officer | — | male |
| Gerry Zhao | Chief Business Officer | — | male |
| Clive Blower | Chief Operations Officer | — | — |
| Lauren Frazer | Chief Financial Officer & Company Secretary | — | female |
| Lawrence Glass | Chief Science Officer | — | male |
| Liza A. Squires | Chief Medical Officer | — | — |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for NEU.AX
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
